- BTIG reiterated its “Buy” rating for Harrow Health (NASDAQ:HROW), indicating confidence in the company’s growth potential.
- Harrow Health announced the acceptance of three scientific abstracts at the ASCRS 2026 Annual Meeting, highlighting its commitment to ophthalmic disease management.
- The company’s stock has shown fluctuations, with a current price of $34, reflecting a 2.16% increase.
Harrow Health (NASDAQ:HROW) is a key player in the field of ophthalmic disease management in North America. The company focuses on providing innovative solutions for eye-related conditions. Harrow’s products, such as VEVYE® and ILEVRO®, are designed to address issues like dry eye disease and post-cataract surgery complications. The company competes with other pharmaceutical firms in the ophthalmic sector.
On March 18, 2026, BTIG reiterated its “Buy” rating for Harrow Health, maintaining its previous grade. At that time, the stock was priced at $35.36. This endorsement reflects confidence in Harrow’s potential for growth and its strategic initiatives in the ophthalmic field. The company’s commitment to advancing treatment options is evident in its recent achievements.
Harrow recently announced that three scientific abstracts featuring its products, VEVYE® and ILEVRO®, have been accepted for presentation at the American Society of Cataract and Refractive Surgery (ASCRS) 2026 Annual Meeting. This event, scheduled for April 10-13 in Washington, D.C., underscores Harrow’s dedication to evidence-based treatment advancements. The presentations will focus on ocular surface disease, highlighting the company’s research efforts.
Currently, HROW’s stock is priced at $34, reflecting a 2.16% increase or $0.72. The stock has experienced fluctuations, with a low of $33.03 and a high of $34.87 during the trading day. Over the past year, HROW has seen a high of $54.85 and a low of $20.85. The company’s market capitalization is approximately $1.27 billion, with a trading volume of 634,468 shares on the NASDAQ exchange.
